Lumakras (sotorasib) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...27282930313233343536373839»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Clinical Data for KRAS G12C Inhibitors (Scientific Program Auditorium) -  Dec 4, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_213;    
    Currently the phase 3 CodeBreak 200 trial of sotorasib in combination with docetaxel is recruiting patients with locally advanced and unresectable or metastatic NSCLC with KRAS G12C who are previously treated with 1 prior therapy...The agent was also administered in combination with either pembrolizumab, afatinib, or cetuximab in various expansion cohorts...Treatment with adagrasib in KRYTAL-1 led to TRAEs of any grade in 85% of the population, as well as grade 3/4 TRAEs in 30% and grade 5 TRAEs in 2%. Upcoming trials exploring KRAS inhibition would be phase 1 studies of JNJ-74699157 and GDC-6036 as treatment of patients with KRAS G12C mutations.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  KRAS Inhibition with Sotorasib in Advanced Solid Tumors. (Pubmed Central) -  Oct 21, 2020   
    P1/2
    Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
  • ||||||||||  sotorasib (AMG 510) / Amgen
    [VIRTUAL] Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1153;    
    The CodeBreak 100 trial revealed that a novel KRASG12C inhibitor, AMG510, has an attractive anti-tumor effect against KRASG12C-mutant solid tumors, including mCRC...Legal entity responsible for the study: Hironaga Satake. Funding: Has not received any funding.
  • ||||||||||  sotorasib (AMG 510) / Amgen
    [VIRTUAL] Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_788;    
    The CodeBreak 100 trial revealed that a novel KRASG12C inhibitor, AMG510, has an attractive anti-tumor effect against KRASG12C-mutant solid tumors, including mCRC...Minor RAS-mutant tumors were associated with significantly shorter survival times than those associated with RAS wild-type {hazard ratio (HR)=2.65 [95% confidence interval (CI), 0.99 to 7.07], p=0.043} and major RAS-mutant tumors (HR=5.15 [95% CI, 1.56 to 16.98], p=0.003). This multicenter study revealed the clinical and prognostic features in Japanese patients with detailed RAS/BRAFV600E-mutant mCRC.
  • ||||||||||  sotorasib (AMG 510) / Amgen
    [VIRTUAL] Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_414;    
    The CodeBreak 100 trial revealed that a novel KRASG12C inhibitor, AMG510, has an attractive anti-tumor effect against KRASG12C-mutant solid tumors, including mCRC...Minor RAS-mutant tumors were associated with significantly shorter survival times than those associated with RAS wild-type {hazard ratio (HR)=2.65 [95% confidence interval (CI), 0.99 to 7.07], p=0.043} and major RAS-mutant tumors (HR=5.15 [95% CI, 1.56 to 16.98], p=0.003). This multicenter study revealed the clinical and prognostic features in Japanese patients with detailed RAS/BRAFV600E-mutant mCRC.
  • ||||||||||  sotorasib (AMG 510) / Amgen
    Journal:  KRAS Inhibitor Continues to Impress in NSCLC. (Pubmed Central) -  Oct 4, 2020   
    Evidence continues to grow that KRAS, once considered an "undruggable" target, can be targeted successfully in non-small cell lung cancer. In a phase I trial, the KRAS inhibitor sotorasib elicited responses in about a third of patients with the disease and was generally well tolerated.